0000899866-18-000037.txt : 20180208 0000899866-18-000037.hdr.sgml : 20180208 20180208191624 ACCESSION NUMBER: 0000899866-18-000037 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180206 FILED AS OF DATE: 20180208 DATE AS OF CHANGE: 20180208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Moriarty John B CENTRAL INDEX KEY: 0001564621 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-27756 FILM NUMBER: 18587124 MAIL ADDRESS: STREET 1: ALEXION PHARMACEUTICALS STREET 2: 352 KNOTTER DRIVE CITY: CHESHIRE STATE: CT ZIP: 06410 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000899866 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133648318 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 COLLEGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 BUSINESS PHONE: 2032722596 MAIL ADDRESS: STREET 1: 100 COLLEGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06510 4 1 wf-form4_151813537006905.xml FORM 4 X0306 4 2018-02-06 0 0000899866 ALEXION PHARMACEUTICALS INC ALXN 0001564621 Moriarty John B C/O ALEXION PHARMACEUTICALS, INC 100 COLLEGE STREET NEW HAVEN CT 06510 0 1 0 0 EVP & General Counsel Common Stock, par value $.0001 per share 2018-02-06 4 A 0 21489 0 A 71400 D Common Stock, par value $.0001 per share 2018-02-06 4 A 0 6500 0 A 77900 D Common Stock, par value $.0001 per share 2018-02-08 4 S 0 2163 115.70 D 75737 D Common Stock, par value $.0001 per share 2018-02-08 4 S 0 1200 115.70 D 74537 D On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 21,489 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary. On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 6,500 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/4 of such shares vested on February 6, 2018 and 1/4 vest on each subsequent anniversary. This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $115.20 - $116.20. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.25 - $117.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. /s/ Michael Greco, Attorney-in-Fact for John B. Moriarty 2018-02-08